Abstract
Vascular smooth muscle cell (VSMC) proliferation and migration has been correlated with intimai hyperplasia (IH) after vascular interventions such as angioplasty, stenting, and vascular graft surgery. Therefore, therapies targeting inhibition of VSMC migration may lead to higher patency rates in vascular grafts and reduced IH in other vascular interventions. This study tested three targeted therapies and their combinations: hyperfunctional α vβ 3 integrin expression, cyclic-RGD release and tissue inhibitor of metalloprotease (TIMP)-1 release. It was found that a combination of 1.0 mM cyclic-RGD and 10 ng/mL TIMP-1 maximally inhibited smooth muscle cell invasion over individual or other combinations of treatments over 72 hours.
| Original language | English (US) |
|---|---|
| Title of host publication | Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings |
| Editors | R.S. Leder |
| Pages | 1215-1218 |
| Number of pages | 4 |
| Volume | 2 |
| State | Published - 2003 |
| Event | A New Beginning for Human Health: Proceddings of the 25th Annual International Conference of the IEEE Engineering in Medicine and Biology Society - Cancun, Mexico Duration: Sep 17 2003 → Sep 21 2003 |
Other
| Other | A New Beginning for Human Health: Proceddings of the 25th Annual International Conference of the IEEE Engineering in Medicine and Biology Society |
|---|---|
| Country/Territory | Mexico |
| City | Cancun |
| Period | 9/17/03 → 9/21/03 |
Keywords
- Hyperplasia
- Integrin
- Invasion
- Migration
- Peptide
- Smooth muscle cells
ASJC Scopus subject areas
- Bioengineering